Resistance mechanisms to mTOR inhibition in renal cancer

<p><b>Introduction</b>: Advanced clear cell renal cell cancer (CCRCC) is incurable, but molecularly targeted treatments have improved the prognosis. One such molecular target is the mammalian target of rapamycin (mTOR) and two rapalogues (everolimus and temsirolimus) have been lice...

詳細記述

書誌詳細
第一著者: Earwaker, P
その他の著者: Macaulay, V
フォーマット: 学位論文
言語:English
出版事項: 2015

類似資料